

# Radoslaw Zagozdzon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6203336/radoslaw-zagozdzon-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78  
papers

1,385  
citations

20  
h-index

34  
g-index

93  
ext. papers

1,714  
ext. citations

5.4  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
78	Accuracy of virtual crossmatch (VXM) prediction of physical crossmatch (PXM) results of donor specific antibody (DSA) in routine pretransplant settings-A single-center experience.. <i>Transplant Immunology</i> , <b>2022</b> , 101583	1.7	1
77	PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress. <i>Cancer Immunology Research</i> , <b>2021</b> ,	12.5	3
76	Bioinformatic Analysis Reveals Central Role for Tumor-Infiltrating Immune Cells in Uveal Melanoma Progression. <i>Journal of Immunology Research</i> , <b>2021</b> , 2021, 9920234	4.5	1
75	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) with a New Pathogenic Variant in Gene in a Family of the Adult Male with Renal AA Amyloidosis-Diagnostic and Therapeutic Challenge for Clinicians. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
74	Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis.. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2021</b> , 70, 3	4	0
73	Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells. <i>Cells</i> , <b>2020</b> , 9,	7.9	3
72	Comparative Study of Immunomodulatory Agents to Induce Human T Regulatory (Treg) Cells: Preferential Treg-Stimulatory Effect of Prednisolone and Rapamycin. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2020</b> , 68, 20	4	2
71	Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. <i>Cancers</i> , <b>2020</b> , 12,	6.6	14
70	Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer Cells. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	9
69	Inactivation of IgM Antibodies as a Crucial Element of Diagnostics in Sensitized Patients Awaiting Kidney Transplant. <i>Transplantation Proceedings</i> , <b>2020</b> , 52, 2268-2272	1.1	0
68	Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells. <i>Blood</i> , <b>2020</b> , 136, 24-25	2.2	
67	Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy. <i>Cancer Letters</i> , <b>2020</b> , 471, 1-11	9.9	14
66	Prospects for NK Cell Therapy of Sarcoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
65	Osteopontin Gene Polymorphism and Urinary OPN Excretion in Patients with Immunoglobulin A Nephropathy. <i>Cells</i> , <b>2019</b> , 8,	7.9	4
64	Selenium-containing polysaccharides from <i>Lentinula edodes</i> -Biological activity. <i>Carbohydrate Polymers</i> , <b>2019</b> , 223, 115078	10.3	12
63	Monoclonal Antibodies in Dermatocology-State of the Art and Future Perspectives. <i>Cancers</i> , <b>2019</b> , 11,	6.6	6
62	Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	53

61	Sildenafil Citrate Influences Production of TNF- in Healthy Men Lymphocytes. <i>Journal of Immunology Research</i> , <b>2019</b> , 2019, 8478750	4.5	3
60	Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2019</b> , 67, 79-88	4	12
59	Inhibition of thioredoxin-dependent HO removal sensitizes malignant B-cells to pharmacological ascorbate. <i>Redox Biology</i> , <b>2019</b> , 21, 101062	11.3	24
58	Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 467-480	12.5	49
57	Application of Genome Editing Techniques in Immunology. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2018</b> , 66, 289-298	4	11
56	Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. <i>BMC Cancer</i> , <b>2018</b> , 18, 210	4.8	25
55	Oxidative Stress in Kidney Diseases: The Cause or the Consequence?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2018</b> , 66, 211-220	4	49
54	Intraurethral co-transplantation of bone marrow mesenchymal stem cells and muscle-derived cells improves the urethral closure. <i>Stem Cell Research and Therapy</i> , <b>2018</b> , 9, 239	8.3	11
53	Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 873-884	8.7	26
52	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. <i>BMC Cancer</i> , <b>2018</b> , 18, 965	4.8	13
51	Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , <b>2018</b> , 50, 1720-1725	1.1	1
50	New insights into redox homeostasis as a therapeutic target in B-cell malignancies. <i>Current Opinion in Hematology</i> , <b>2017</b> , 24, 393-401	3.3	20
49	The Anatomy of Caprine Female Urethra and Characteristics of Muscle and Bone Marrow Derived Caprine Cells for Autologous Cell Therapy Testing. <i>Anatomical Record</i> , <b>2017</b> , 300, 577-588	2.1	9
48	In vivo imaging system for explants analysis-A new approach for assessment of cell transplantation effects in large animal models. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184588	3.7	9
47	Clinical Trials with IL-12 in Cancer Immunotherapy. <i>SpringerBriefs in Immunology</i> , <b>2016</b> , 43-75		1
46	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 1717-313	3.3	41
45	Biology of IL-12. <i>SpringerBriefs in Immunology</i> , <b>2016</b> , 1-19		0
44	Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. <i>Immunology</i> , <b>2015</b> , 146, 173-83	7.8	15

43	Cancer stem cells in haematological malignancies. <i>Współczesna Onkologia</i> , <b>2015</b> , 19, A1-6	1	14
42	Interleukin 12: still a promising candidate for tumor immunotherapy?. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 419-35	7.4	261
41	In silico analysis of microRNA-510 as a potential oncomir in human breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 403	8.3	3
40	Dynamics of acute local inflammatory response after autologous transplantation of muscle-derived cells into the skeletal muscle. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 482352	4.3	7
39	Statins impair glucose uptake in human cells. <i>BMJ Open Diabetes Research and Care</i> , <b>2014</b> , 2, e000017	4.5	31
38	Peroxiredoxin-1 protects estrogen receptor $\beta$ from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R79	8.3	37
37	Adenanthin targets proteins involved in the regulation of disulphide bonds. <i>Biochemical Pharmacology</i> , <b>2014</b> , 89, 210-6	6	30
36	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. <i>Blood</i> , <b>2014</b> , 124, 1693-1693.2	3.2	1
35	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. <i>BMC Cancer</i> , <b>2013</b> , 13, 175	4.8	36
34	The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER $\beta$ and is an independent prognostic factor in node-negative breast cancer. <i>Oncogene</i> , <b>2012</b> , 31, 3483-94	9.2	7
33	Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. <i>BMC Cancer</i> , <b>2012</b> , 12, 209	4.8	6
32	Truncated HER2: implications for HER2-targeted therapeutics. <i>Drug Discovery Today</i> , <b>2011</b> , 16, 810-6	8.8	20
31	NRP/B mutations impair Nrf2-dependent NQO1 induction in human primary brain tumors. <i>Oncogene</i> , <b>2009</b> , 28, 378-89	9.2	17
30	Csk homologous kinase inhibits CXCL12-CXCR4 signaling in neuroblastoma. <i>International Journal of Oncology</i> , <b>2008</b> , 32, 619-23	1	1
29	Csk homologous kinase (CHK), unlike Csk, enhances MAPK activation via Ras-mediated signaling in a Src-independent manner. <i>Cellular Signalling</i> , <b>2006</b> , 18, 871-81	4.9	10
28	Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. <i>Cancer Research</i> , <b>2006</b> , 66, 5757-62	10.1	8
27	CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion <b>2006</b> , 29, 1453		4
26	Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1 $\alpha$ )-mediated breast cancer cell migration. <i>Cancer Research</i> , <b>2005</b> , 65, 2840-5	10.1	35

25	Use of antisense oligonucleotide technology to investigate signaling pathways in megakaryocytes. <i>Methods in Molecular Biology</i> , <b>2004</b> , 273, 397-406	1.4	
24	Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors. <i>Cancer</i> , <b>2004</b> , 101, 1018-27	6.4	12
23	Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration <b>2002</b> , 21, 197		1
22	Overexpression of the Csk homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells <b>2002</b> , 21, 1347		
21	Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 36465-70	5.4	18
20	IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. <i>Oncology Reports</i> , <b>2002</b> , 9, 427-31	3.5	3
19	Overexpression of the Csk homologous kinase facilitates phosphorylation of Akt/PKB in MCF-7 cells. <i>International Journal of Oncology</i> , <b>2002</b> , 21, 1347-52	1	2
18	Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. <i>Leukemia</i> , <b>2001</b> , 15, 613-20	10.7	15
17	Direct stimulation of macrophages by IL-12 and IL-18--a bridge too far?. <i>Immunology Letters</i> , <b>2000</b> , 72, 153-7	4.1	28
16	Effect of viral infection on T-cell apoptosis in allograft recipients. <i>Transplantation Proceedings</i> , <b>2000</b> , 32, 1403-5	1.1	
15	Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. <i>Life Sciences</i> , <b>2000</b> , 66, 1223-30	6.8	10
14	Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 1485-91	8.7	44
13	Potentiated anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. <i>Oncology Reports</i> , <b>2000</b> , 7, 177-81	3.5	8
12	Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review). <i>International Journal of Molecular Medicine</i> , <b>1999</b> , 3, 537-44	4.4	44
11	Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. <i>International Journal of Molecular Medicine</i> , <b>1999</b> , 4, 645-8	4.4	7
10	The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. <i>Cancer Letters</i> , <b>1999</b> , 147, 67-75	9.9	9
9	Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. <i>International Journal of Cancer</i> , <b>1998</b> , 77, 720-7	7.5	36
8	Calcitriol enhances antineoplastic and antiangiogenic effects of interleukin-12. <i>Archives of Dermatological Research</i> , <b>1998</b> , 290, 696-700	3.3	4

7	Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 406-11	7.5	75
6	Re: Greying of America will foster new strategies in oncology. <i>Journal of the National Cancer Institute</i> , <b>1998</b> , 90, 247-8	9.7	3
5	Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. <i>Tumor Biology</i> , <b>1998</b> , 19, 77-87	2.9	9
4	G-CSF prevents the suppression of bone marrow hematopoiesis induced by IL-12 and augments its antitumor activity in a melanoma model in mice. <i>Annals of Oncology</i> , <b>1998</b> , 9, 63-9	10.3	21
3	Erythropoietin Prevents the Development of Interleukin-12 Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. <i>Blood</i> , <b>1998</b> , 91, 4387-4388	2.2	12
2	Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , <b>1997</b> , 2, 455-62	5.4	18
1	Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. <i>International Journal of Cancer</i> , <b>1996</b> , 66, 374-9	7.5	23